Belumosudil for Long‐Standing Refractory Chronic Graft‐Versus‐Host Disease: A Two‐Patient Case Report
ABSTRACT In long‐standing fibrotic chronic GVHD refractory to multiple systemic therapies, belumosudil may provide clinically meaningful patient‐reported improvement and reduce infection‐related hospitalizations even when early NIH organ scores remain stable. When benefits are evident and safety is acceptable, continuation beyond 3–6 months may be reasonable.
Authors
- Jae‐Sook Ahn (ORCID: https://orcid.org/0000-0003-3078-5024)
- Ga‐Young Song (ORCID: https://orcid.org/0000-0002-5203-2982)
- Sung‐Hoon Jung (ORCID: https://orcid.org/0000-0003-3370-3987)
- Mihee Kim (ORCID: https://orcid.org/0000-0002-2781-8633)
- Ho Cheol Jang (ORCID: https://orcid.org/0009-0000-1155-2298)
- Seo‐Yeon Ahn
Institutions
- Chonnam National University Hwasun Hospital (KR)
Publication Details
- Journal
- Clinical Case Reports
- Published
- 2026-06-25
- DOI
- https://doi.org/10.1002/ccr3.73050
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00